FDA approves ZymoGenetics' rThrombin

ZymoGenetics has received FDA approval to market rThrombin, a surgical blood clotting product. The drug is a recombinant form of human thrombin; previous treatments were derived from human or animal blood. ZymoGenetics says that production of the new drug doesn't depend on the availability of animal or human blood and can therefore be scaled-up to meet market demand.

The drug, to be sold under the name Recothrom, was acquired by Bayer last year in a $198 million deal. The FDA approval triggers a $40 million milestone payment to ZymoGenetics.

- see this release for more

ALSO: Check out the 17 new drugs that received FDA approval last year. List

Suggested Articles

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.